A Phase 3 interventional study of DTG/3TC in HIV and HIV Infections, sponsored by ViiV Healthcare. Completed at 56 sites in 12 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 16th largest by enrollment, is one of 5 that started in 2023, is one of 21 in phase 3, and was the 46th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 63rd largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2023, is one of 65 in phase 3, and was the 234th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in participants living with Human Immunodeficiency Virus Type 1 (HIV-1) who are of at least 50 years of age and above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence of virus (HBV) infection was based on the results of testing at Screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs) and HBV deoxyribonucleic acid (DNA) as follows:
(ALT) was ≥5 times the (ULN) or ALT was ≥3×ULN and was ≥1.5×ULN (>35% direct bilirubin).
- Participants had estimated creatine clearance \<30 mL/min per 1.73 square meter (m\^2) using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R) method.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants living with HIV switched from Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) on Day 1 and received once daily dose of DTG/3TC FDC for 96 weeks. At Week 96, all participants switched to locally available DTG/3TC FDC or local standard of care (SOC) Antiretroviral Therapy (ART).
Drug: DTG/3TC
Drug pages: Dolutegravir · Lamivudine
DTG/3TC FDC was administered once daily.
Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=)50 Copies/Millilitre (c/mL) at Week 48
Participants with HIV-1 RNA \>= 50 c/mL were evaluated. Virologic outcome was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the Week 48 Window. The analysis was done using the modified Snapshot algorithm.
Time frame: At Week 48
Number of Participants With Plasma HIV-1 RNA >= 50 c/mL at Week 24
The number of participants with plasma HIV-1 RNA \>/=50 c/mL at Week 24 was analyzed using the Snapshot Algorithm.
Time frame: At Week 24
Number of Participants With Plasma HIV-1 RNA >= 50 c/mL at Week 96
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: At Week 96
Number of Participants With Plasma HIV-1 RNA Less Than (<) 50 c/mL at Week 24
The number of participants with plasma HIV-1 RNA \<50 c/mL at Week 24 was analyzed using the Snapshot Algorithm.
Time frame: At Week 24
Number of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 48
The number of participants with plasma HIV-1 RNA \< 50 c/mL at Week 48 was analyzed using the modified Snapshot Algorithm.
Time frame: At Week 48
Number of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 96
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: At Week 96
Absolute Values for Cluster of Differentiation 4 (CD4+) Cells Count at Week 24
Time frame: At Week 24
Absolute Values for CD4+ Cells Count at Week 48
Time frame: At Week 48
Absolute Values for CD4+ Cells Count at Week 96
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: At Week 96
Absolute Values for CD4: Cluster of Differentiation 8 (CD8) Ratio at Week 24
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
Time frame: At Week 24
Absolute Values for CD4:CD8 Ratio at Week 48
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
Time frame: At Week 48
Absolute Values for CD4:CD8 Ratio at Week 96
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: At Week 96
Change From Baseline in CD4+ Cells Count at Week 24
Time frame: At Week 24 compared to Baseline
Change From Baseline in CD4+ Cells Count at Week 48
Time frame: At Week 48 compared to Baseline
Change From Baseline in CD4+ Cells Count at Week 96
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: At Week 96 compared to baseline
Change From Baseline in CD4:CD8 Ratio at Week 24
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
Time frame: At Week 24 compared to Baseline
Change From Baseline in CD4:CD8 Ratio at Week 48
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
Time frame: At Week 48 compared to Baseline
Change From Baseline in CD4:CD8 Ratio at Week 96
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: At Week 96 compared to baseline
Number of Participants With Disease Progression (HIV-associated Conditions, AIDS, and Death) Through Week 24
Occurrence of disease progression was evaluated through HIV-associated conditions and incidence of disease progression to United States Centers for Disease Control and Prevention (CDC) stage 3 or death.
Time frame: Up to Week 24
Number of Participants With Disease Progression (HIV-associated Conditions, AIDS, and Death) Through Week 48
Time frame: Up to Week 48
Number of Participants With Disease Progression (HIV-associated Conditions, AIDS, and Death) Through Week 96
Time frame: Week 96
Number of Participants With Viral Resistance After Meeting Confirmed Virologic Withdrawal (CVW) Criterion
Confirmed virologic withdrawal criteria is defined as two consecutive assessments with HIV-1 RNA greater than or equal to (\>=)200 c/mL after Day 1 visit.
Time frame: Up to Week 48
Number of Participants With Viral Resistance After Meeting CVW Criterion
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: From Week 48 to Week 96
Number of Participants With Treatment Related Non-serious Adverse Events (AEs)
A treatment related non-serious AE is defined as any untoward medical occurrence in a clinical study participant considered related to the study treatment. Any = occurrence of the event regardless of intensity grade
Time frame: Up to Week 48
Number of Participants With Treatment Related Non-serious AEs
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: From Week 48 to Week 96
Number of Participants With Any Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. Any = occurrence of the event regardless of intensity grade.
Time frame: Up to Week 48
Number of Participants With SAEs
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: From Week 48 to Week 96
Number of Participants With AEs Leading to Treatment Discontinuation
Time frame: Up to Week 48
Number of Participants With AEs Leading to Treatment Discontinuation
Data not available at the time of posting, will be updated at the final results disclosure stage.
Time frame: From Week 48 to Week 96
| Milestone | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Started | 205 |
| Completed | 175 |
| Not completed | 30 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Adverse event | 5 |
| Withdrew: Death | 1 |
| Withdrew: Participant reached protocol defined stopping criteria | 15 |
Participants with HIV-1 RNA \>= 50 c/mL were evaluated. Virologic outcome was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the Week 48 Window. The analysis was done using the modified Snapshot algorithm.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=)50 Copies/Millilitre (c/mL) at Week 48 | 2 |
The number of participants with plasma HIV-1 RNA \>/=50 c/mL at Week 24 was analyzed using the Snapshot Algorithm.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With Plasma HIV-1 RNA >= 50 c/mL at Week 24 | 14 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
The number of participants with plasma HIV-1 RNA \<50 c/mL at Week 24 was analyzed using the Snapshot Algorithm.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Participants with Plasma HIV-1 RNA < 50 c/mL | 183 |
| Participants with no virologic data | 8 |
The number of participants with plasma HIV-1 RNA \< 50 c/mL at Week 48 was analyzed using the modified Snapshot Algorithm.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Participants with Plasma HIV-1 RNA < 50 c/mL | 177 |
| Participants with no virologic data | 26 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
| cells per cubic millimeter (cells/mm^3) | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Absolute Values for Cluster of Differentiation 4 (CD4+) Cells Count at Week 24 | 724.8 ± 322.69 |
| cells/mm^3 | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Absolute Values for CD4+ Cells Count at Week 48 | 723.6 ± 334.76 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
| Ratio | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Absolute Values for CD4: Cluster of Differentiation 8 (CD8) Ratio at Week 24 | 1.127 ± 0.5861 |
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
| Ratio | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Absolute Values for CD4:CD8 Ratio at Week 48 | 1.210 ± 0.6203 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
| cells/mm^3 | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Baseline | 733.6 ± 313.32 |
| Week 24 | -8.9 ± 162.16 |
| cells/mm^3 | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Baseline | 733.6 ± 313.32 |
| Week 48 | -16.8 ± 190.56 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
| Ratio | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Baseline | 1.167 ± 0.6125 |
| Week 24 | -0.027 ± 0.2325 |
The CD4/CD8 ratio is defined as a numerical representation of the proportion of CD4+ T cells to CD8+ T cells in the blood.
| Ratio | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Baseline | 1.167 ± 0.6125 |
| Week 48 | 0.030 ± 0.2065 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
Occurrence of disease progression was evaluated through HIV-associated conditions and incidence of disease progression to United States Centers for Disease Control and Prevention (CDC) stage 3 or death.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With Disease Progression (HIV-associated Conditions, AIDS, and Death) Through Week 24 | 4 |
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With Disease Progression (HIV-associated Conditions, AIDS, and Death) Through Week 48 | 6 |
Results for this outcome have not been posted.
Confirmed virologic withdrawal criteria is defined as two consecutive assessments with HIV-1 RNA greater than or equal to (\>=)200 c/mL after Day 1 visit.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With Viral Resistance After Meeting Confirmed Virologic Withdrawal (CVW) Criterion | 0 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
A treatment related non-serious AE is defined as any untoward medical occurrence in a clinical study participant considered related to the study treatment. Any = occurrence of the event regardless of intensity grade
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With Treatment Related Non-serious Adverse Events (AEs) | 17 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. Any = occurrence of the event regardless of intensity grade.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With Any Serious Adverse Events (SAEs) | 26 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
| Participants | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Number of Participants With AEs Leading to Treatment Discontinuation | 9 |
Data not available at the time of posting, will be updated at the final results disclosure stage.
Results for this outcome have not been posted.
Collected over Adverse events (AEs), Serious AEs (SAEs) and all-cause mortality were collected from Day 1 through Week 96. Results up to Week 48 are presented. Safety data post-week 48 will be provided at the final results disclosure stage.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) | 2/205 (1%) | 26/205 (12.7%) | 69/205 (33.7%) |
| Event | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 2/205 |
| Alcohol poisoningInjury, poisoning and procedural complications | 1/205 |
| Head injuryInjury, poisoning and procedural complications | 1/205 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/205 |
| Medication errorInjury, poisoning and procedural complications | 1/205 |
| Periprosthetic fractureInjury, poisoning and procedural complications | 1/205 |
| Radius fractureInjury, poisoning and procedural complications | 1/205 |
| Skin injuryInjury, poisoning and procedural complications | 1/205 |
| Complicated appendicitisInfections and infestations | 1/205 |
| DiverticulitisInfections and infestations | 1/205 |
| Event | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/205 |
| HeadacheNervous system disorders | 15/205 |
| DiarrhoeaGastrointestinal disorders | 10/205 |
| NauseaGastrointestinal disorders | 9/205 |
| FatigueGeneral disorders | 9/205 |
| COVID-19Infections and infestations | 9/205 |
| Upper respiratory tract infectionInfections and infestations | 8/205 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/205 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/205 |
| DizzinessNervous system disorders | 6/205 |
| Age, Continuous(Years) | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Mean | 62.2 ± 7.46 |
| Sex: Female, Male(Participants) | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| Female | 88 |
| Male | 117 |
| Race/Ethnicity, Customized(Participants) | Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose Combination (FDC) |
|---|---|
| American Indian or Alaska Native | 4 |
| Asian | 3 |
| Black or African American | 68 |
| White | 125 |
| Multiple | 1 |
| Not reported | 1 |
| Unknown | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Jul 2023 to primary completion in Jan 2026, 30 months.
Results were first posted in May 2026, 3 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 30 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dolutegravir · Lamivudine